Log in to save to my catalogue

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of im...

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of im...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1315200039

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

About this item

Full title

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Publisher

Kidlington: Elsevier Ltd

Journal title

The Lancet (British edition), 2013-01, Vol.381 (9863), p.295-302

Language

English

Formats

Publication information

Publisher

Kidlington: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or un...

Alternative Titles

Full title

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1315200039

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1315200039

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(12)61857-1

How to access this item